Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal？ Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil

Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the treatment of schizophrenia in adults, can be started with either 21？days of daily oral aripiprazole supplementation or a 1-day initiation regimen consisting of a single injection of a NanoCrystal？ Dispersion formulation of AL (ALNCD) and a single dose of 30？mg oral aripiprazole. This phase I study assessed the pharmacokinetics and safety of deltoid versus gluteal ALNCD injections